This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

EANM 2024

Highlights from the Annual Congress of the European Association of Nuclear Medicine

The 37th Annual Congress of the European Association of Nuclear Medicine (EANM) 2024 recently concluded at the CCH Congress Center in Hamburg, marking a successful gathering from October 19–23. ITM was pleased to participate and contribute to this important congress, which brought together over 8,000 participants to showcase pioneering developments in nuclear medicine and oncology, offering insights that will help shape the future of healthcare.

Presentation Highlights

At EANM 2024, ITM contributed to two expert-led presentations aligned to our clinical development programs. These abstracts focused on innovative treatments for prostate cancer (ITM-23) and gastroenteropancreatic neuroendocrine tumors (ITM-63):

  • Interim results from the Phase 0 study on therapy with the somatostatin receptor antagonist DOTA-LM3 labeled with terbium-161, aimed at treating gastroenteropancreatic neuroendocrine tumors Presented by: Dr. Julia Fricke, Universitätsspital Basel, Switzerland
  • Phase Ia/b study on targeted radionuclide therapy in metastatic prostate cancer using a new PSMA ligand radiolabeled with terbium-161 ([161Tb]TbSibuDAB) Presented by: Dr. Alin-Florin Chirindel, Universitätsspital Basel, Switzerland

 

EANM Marie Curie Award

A longstanding tradition at the EANM is the presentation of the prestigious EANM Marie Curie Award, which honors outstanding research contributions in nuclear medicine. This award recognizes scientific excellence, innovation, and advancements in the field. Named after the pioneering scientist Marie Curie, it celebrates groundbreaking research while promoting collaboration and knowledge exchange within the nuclear medicine community.

ITM extends its congratulations to Dr. Julia Fricke from University Hospital Basel (USB) and her co-presenters for receiving the EANM Marie Curie Award at the 37th Annual Congress of EANM 2024.

Dr. Fricke and her team were recognized for their award-winning abstract:
“Therapy with the somatostatin receptor antagonist DOTA-LM3 labeled with terbium-161: Interim results of the Phase 0 Study in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs).”

TM is proud that this award-winning abstract highlights collaborations from our clinical development program focusing on GEP NETs (ITM-63). The abstract is available on the EANM website.

Conference Newsflash Presented by Dr. Karolien Goffin and Dr. Ken Herrmann


Day 1

Nuclear medicine experts Dr. Karolien Goffin and Prof. Dr. Ken Herrmann provided daily insights into the latest advancements at the 2024 Annual Congress of the European Association of Nuclear Medicine (EANM). Explore their perspectives as they introduce the key highlights from each day of this premier event.

Day 2

On Day 2 of EANM 2024, Dr. Karolien Goffin and Prof. Dr. Ken Herrmann shared key insights from the plenary sessions and explored the congress’s scientific topics live from the Congress Center in Hamburg. In the video below, they spotlight the esteemed EANM Marie Curie Award-winning abstract and discuss the latest advancements in theranostics

Day 3

On Day 3 of EANM 2024, Dr. Karolien Goffin and Prof. Dr. Ken Herrmann concluded the day by spotlighting several groundbreaking developments. A central theme was the transformative impact of PSMA PET in prostate cancer management, now vital for both initial diagnosis and cases of biochemical recurrence and re-staging. The day also featured top-rated abstracts and plenary sessions, emphasizing advancements in this area. Additional discussions explored how nuclear medicine is addressing a range of clinical indications, particularly in NET cancer. They also shared insights from a roundtable on healthcare systems' readiness for targeted radiopharmaceutical therapies.

Day 4

As the remarkable 2024 Annual Congress of the European Association of Nuclear Medicine (EANM) comes to a close, Dr. Karolien Goffin and Prof. Dr. Ken Herrmann share their top three highlights from this year’s event.

Day 5

Advancing Innovation Through Collaboration"As we wrap up the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) 2024, ITM extends gratitude to all our guests and industry partners who visited our booth. Building and strengthening collaborations are essential in driving innovation to help improve the lives of patients.

ITM's CEO, Andrew Cavey, explains why collaboration is essential in the biotech and pharma industries:

Thank you for Signing our Donation Wall

We would like to extend our heartfelt thanks to all the visitors at our booth who signed our Signature Wall to raise donations for the Deutsche Hirntumorhilfe e.V. We are pleased to announce that we are rounding up the total donation amount to €5,000!

The Deutsche Hirntumorhilfe e.V. (German Brain Tumor Aid) is an organization dedicated to supporting brain tumor patients and their families. They focus on raising awareness, providing information, and funding research to improve treatment options and quality of life for those affected by brain tumors.
 

Thank you for Signing our Donation Wall

We would like to extend our heartfelt thanks to all the visitors at our booth who signed our Signature Wall to raise donations for the Deutsche Hirntumorhilfe e.V. We are pleased to announce that we are rounding up the total donation amount to €5,000!

The Deutsche Hirntumorhilfe e.V. (German Brain Tumor Aid) is an organization dedicated to supporting brain tumor patients and their families. They focus on raising awareness, providing information, and funding research to improve treatment options and quality of life for those affected by brain tumors.
 

See you next year at EANM 2025 in Barcelona

Save the date: EANM 2025 will be held in Barcelona from October 4–8. We look forward to connecting with you there!